KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Revenue (2016 - 2025)

Teva Pharmaceutical Industries' Revenue history spans 10 years, with the latest figure at $4.7 billion for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 62.45% year-over-year to $4.7 billion, compared with a TTM value of $17.3 billion through Dec 2025, up 13.43%, and an annual FY2025 reading of $17.3 billion, up 4.32% over the prior year.
  • Revenue for Q4 2025 was $4.7 billion at Teva Pharmaceutical Industries, up from $4.5 billion in the prior quarter.
  • The five-year high for Revenue was $4.7 billion in Q4 2025, with the low at $2.9 billion in Q4 2024.
  • Average Revenue over 5 years is $4.0 billion, with a median of $3.9 billion recorded in 2021.
  • Year-over-year, Revenue tumbled 34.93% in 2024 and then soared 62.45% in 2025.
  • Tracing TEVA's Revenue over 5 years: stood at $4.1 billion in 2021, then fell by 5.27% to $3.9 billion in 2022, then increased by 14.75% to $4.5 billion in 2023, then tumbled by 34.93% to $2.9 billion in 2024, then skyrocketed by 62.45% to $4.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Revenue are $4.7 billion (Q4 2025), $4.5 billion (Q3 2025), and $4.2 billion (Q2 2025).